A series of 30 non-covalent imidazo[1,2-]quinoxaline-based inhibitors of epidermal growth factor receptor (EGFR) were designed and synthesized. EGFR inhibitory assessment (against wild type) data of compounds revealed , , , and as potent EGFR inhibitors with IC values of 211.22, 222.21, 193.18, 223.32 and 221.53 nM, respectively, which were comparable to erlotinib (221.03 nM), a positive control. Furthermore, compounds exhibited excellent antiproliferative activity when tested against cancer cell lines harboring EGFR; A549, a non-small cell lung cancer (NSCLC), HCT-116 (colon), MDA-MB-231 (breast) and gefitinib-resistant NSCLC cell line H1975 harboring EGFR. In particular, compound demonstrated significant inhibitory potential against gefitinib-resistant H1975 cells (IC = 3.65 μM) as compared to gefitinib (IC > 20 μM). Moreover, molecular docking disclosed the binding mode of the to the domain of EGFR (wild type and mutant type), indicating the basis of inhibition. Furthermore, its effects on redox modulation, mitochondrial membrane potential, cell cycle analysis and cell death mode in A549 lung cancer cells were also reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967119 | PMC |
| http://dx.doi.org/10.3390/molecules26051490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis, and anticancer assessment of structural analogues of ()-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-]quinoxaline-2-carbonitrile (6b), an imidazo[1,2-]quinoxaline-based non-covalent EGFR inhibitor.
RSC Med Chem
July 2024
Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab Bathinda 151401 India
In our quest to find improved anticancer therapeutics, we expedite the lead optimization of ()-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-]quinoxaline-2-carbonitrile (6b), an EGFR inhibitor previously discovered in our laboratory through an in-house screening program. The lead optimization was rationally initiated considering the catalytic site of EGFR. We synthesized twenty-nine new analogues of 6b and assessed their anticancer activities.
View Article and Find Full Text PDFIn Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice.
Molecules
August 2022
Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India.
Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-]quinoxaline-based EGFR inhibitor (), which showed promising inhibitory activity against the gefitinib-resistant H1975(L858R/T790M) lung cancer cell line.
View Article and Find Full Text PDFDesign and Synthesis of Non-Covalent Imidazo[1,2-]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.
Molecules
March 2021
Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, Punjab, India.
A series of 30 non-covalent imidazo[1,2-]quinoxaline-based inhibitors of epidermal growth factor receptor (EGFR) were designed and synthesized. EGFR inhibitory assessment (against wild type) data of compounds revealed , , , and as potent EGFR inhibitors with IC values of 211.22, 222.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!